Recent Updates
Recently added Catalysts

Guardian Pharmacy Services, Inc.

GRDNFDA catalysts, PDUFA dates & pipeline intelligence
$49.43
▼ -0.09 · -0.18%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full GRDN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $26.3452W HIGH $50.59
Volume
369.71 K
Value Traded
18.19 M
Short % Float
8.23%
Days to Cover
6.6
+5.13%Week
+23.14%1 Month
+30.08%3 Month
+38%6 Month

Cash Data

Unlock GRDN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
3.13 B
EPS (TTM)
1.18
P/E Ratio
41.88
Ent. Value
3.00 B
Total Shares
63.34 M
Float Shares
26.79 M
Insiders
57.71%
Institutions
47.86%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every GRDN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

GRDN Catalyst Timeline

Dated clinical, regulatory and corporate events for Guardian Pharmacy Services, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Guardian Pharmacy Services, Inc.

1Total events
0Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage

Event history 1

◆AcquisitionCorporate
Guardian Pharmacy Services acquires Wellness Concepts
Unlock the full GRDN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How GRDN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all GRDN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Guardian Pharmacy Services, Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every GRDN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every GRDN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock GRDN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Towns DouglasOfficer (See Remarks)Option 23,450 113,006 held$0.00 09/27/2026
Unlock the full GRDN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in GRDN for Q2 2026.
Unlock every fund holding GRDN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in GRDN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see GRDN ownership
Insider and institutional ownership, quarter by quarter.

GRDN Short Interest

Shares sold short, counted twice a month.

8.23%
Short % of Float
of tradable shares sold short
2.2M
Shares Sold Short
-7.5% vs prior count
6.6 High
Days to Cover
trading days of normal volume to buy every short share back
332.0K
Avg Daily Volume
the average used for days to cover
Unlock GRDN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock GRDN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live GRDN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock GRDN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How GRDN ranks across every disease it competes in

Competitive Position is a premium feature
See how GRDN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

GRDN News

-GRDN
Nov 16, 2026
GRDNConferences/Events
▼ -0.2%today

Guardian Pharmacy Services, Inc. to Participate in Upcoming Citi Annual Global Healthcare Conference

Guardian Pharmacy Services, Inc. will attend the Citi 2026 Global Healthcare Conference in Miami on December 1, 2026. CEO Fred Burke is scheduled to participate in a fireside chat at 2:20 p.m. EST. The event will be accessible via a live audio webcast for investors and the public.

Read more →
-GRDN
Nov 5, 2026
GRDNGeneral
▲ +6.3%on this news· ran to +25% by day 3

Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance

Guardian Pharmacy Services reported strong third-quarter results for 2026, with revenues of $371.1 million and net income of $19.1 million. The company raised its full-year guidance, citing organic growth and margin improvements. CEO Fred Burke emphasized the positive outlook and the company's strategic acquisitions to enhance growth.

Read more →
-GRDN
Nov 2, 2026
GRDNGeneral

Guardian Pharmacy Services Acquires Van’s Institutional Pharmacy, Expanding Footprint in Tennessee and Kentucky

Guardian Pharmacy Services has acquired Van's Institutional Pharmacy, expanding its operations in Tennessee. This acquisition increases Guardian's presence to five pharmacies in the state, enhancing its ability to meet the growing demand for long-term care pharmacy services. Van's will continue to operate under its name, with its existing leadership remaining in place.

Read more →
-GRDN
Nov 2, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc. to Participate in Upcoming Stephens Investment Conference

Guardian Pharmacy Services, Inc. will attend the Stephens Investment Conference on November 18, 2026. CEO Fred Burke is scheduled to participate in a fireside chat at 9:30 a.m. CST. Investors and the public can access a live audio webcast of the presentation via the company's website. Guardian operates 61 licensed pharmacies, serving about 210,000 residents.

Read more →
-GRDN
Oct 21, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc. to Report Third Quarter 2026 Financial Results and Host Conference Call

Guardian Pharmacy Services, Inc. announced it will release its third quarter 2026 financial results on November 5, 2026. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results. Participants can join via audio webcast or by phone.

Read more →
-GRDN
Sep 1, 2026
GRDNGeneral

Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy

Guardian Pharmacy Services, Inc. has successfully acquired the assets of Nautilus Pharmacy, based in Tennessee. This acquisition is expected to enhance Guardian's service offerings and strengthen its market position. The move reflects Guardian's strategy to expand its portfolio and improve its operational capabilities.

Read more →
-GRDN
Aug 19, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference

Guardian Pharmacy Services, Inc. will participate in the Jefferies Healthcare Services Conference on September 15, 2026. CEO Fred Burke is scheduled for a fireside chat at 2:25 p.m. CST. The event is open to investors, analysts, and the public via a live audio webcast.

Read more →
-GRDN
Aug 6, 2026
GRDNGeneral
▲ +11%on this news

Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance

Guardian Pharmacy Services, Inc. reported its financial results for the second quarter of 2026, showing a revenue increase of 2% year-over-year, totaling $351.8 million. The company served approximately 210,000 residents, marking an 8% growth compared to the previous year. Additionally, Guardian raised its full-year guidance, reflecting a positive outlook.

Read more →
-GRDN
Jul 15, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc. to Report Second Quarter 2026 Financial Results and Host Conference Call

Guardian Pharmacy Services, Inc. has announced the release of its second quarter 2026 financial results, which will occur after market close on August 6, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors can access the call via audio webcast or by phone.

Read more →
-GRDN
Jul 1, 2026
GRDNGeneral

Guardian Pharmacy Services Expands Virginia Footprint With Acquisition of Wellness Concepts

Guardian Pharmacy Services has announced the expansion of its operations in Virginia through the acquisition of Wellness Concepts. This move is part of Guardian's strategy to enhance its service offerings in the region. The acquisition aims to strengthen Guardian's market presence and improve access to pharmacy services for clients in Virginia.

Read more →
-GRDN
Jun 22, 2026
GRDNGeneral
▼ -6.4%on this newsshared move

Guardian Pharmacy Services, Inc. Announces Leadership Transitions

Guardian Pharmacy Services, Inc. has announced leadership transitions within the company. The details of these changes were not specified in the article. The announcement indicates a potential shift in company strategy or operations. Further information may be released in the future regarding the new leadership roles.

Read more →
-GRDN
May 12, 2026
GRDNGeneral

Guardian Pharmacy Services Announces Senior Leadership Promotions to Support Continued Growth and Operational Alignment

Guardian Pharmacy Services announced several senior leadership promotions to enhance operational alignment and support growth. Key promotions include Will Mudd as SVP of Finance and Doug Towns as SVP of General Counsel. The company aims to maintain service consistency across its national network while emphasizing local pharmacy leadership.

Read more →
-GRDN
May 6, 2026
GRDNGeneral

Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance

Guardian Pharmacy Services has released its financial results for the first quarter of 2026 and has updated its guidance for the full year. The report indicates ongoing operations but lacks specific details on financial performance or strategic initiatives. The company aims to provide clearer insights as the year progresses.

Read more →
-GRDN
Apr 23, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc. to Participate in the Bank of America 2026 Healthcare Conference

Guardian Pharmacy Services, Inc. will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026. CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT. The event is accessible via a live audio webcast on the company's website, promoting transparency and engagement with stakeholders.

Read more →
-GRDN
Apr 14, 2026
GRDNConferences/Events

Guardian Pharmacy Services, Inc. to Report First Quarter 2026 Financial Results and Host Conference Call

Guardian Pharmacy Services, Inc. is set to report its financial results for the first quarter of 2026. The company will also host a conference call to discuss these results with stakeholders. Further details about the financial performance and insights are expected during the call.

Read more →
-GRDN
Mar 11, 2026
GRDNGeneral

Guardian Pharmacy Services Reports Fourth Quarter and Full Year 2025 Financial Results; Raises 2026 Adjusted EBITDA Guidance

Guardian Pharmacy Services, a leading provider of long-term care pharmacy services, announced its financial results for the fourth quarter and full year of 2025, showcasing strong growth across revenue and Adjusted EBITDA. The company raised its Adjusted EBITDA guidance for 2026, reflecting positive business momentum and operational efficiencies. Additionally, Guardian expanded its full-service pharmacy count with the acquisition of North Ridge Pharmacy, contributing to an overall increase in service capacity and operational performance. The results indicate a focus on long-term sustainable value for shareholders, despite acknowledging the impact of new drug pricing changes scheduled for 2026.

Read more →
-GRDN
Jan 14, 2026
GRDNGeneral

Guardian Pharmacy Services Reiterates 2025 Guidance and Provides 2026 Outlook

Guardian Pharmacy Services has reiterated its 2025 guidance while providing a preliminary outlook for 2026, expecting low double-digit adjusted EBITDA growth. The company anticipates revenue between $1.40 billion and $1.42 billion for 2026, despite drug pricing reforms. CEO Fred Burke emphasized the company's commitment to maintaining care quality while adapting to market changes.

Read more →
-GRDN
Nov 10, 2025
GRDNGeneral

Guardian Pharmacy Services Reports Third Quarter 2025 Financial Results

Guardian Pharmacy Services reported strong financial results for the third quarter of 2025, marking a successful inaugural year as a public company. The company's revenue guidance was raised to between $1.43 billion and $1.45 billion, alongside an increase in Adjusted EBITDA guidance. The expansion into the Pacific Northwest through the acquisition of Managed Healthcare Pharmacy highlights Guardian's growth strategy. The firm also filed a shelf registration statement, allowing for future financing strategies.

Read more →
-GRDN
Sep 18, 2025
GRDNGeneral

Smarter Growth, Better Service Disclaimers Forward-Looking Statements: This presentation (including oral commentary that accompanies this presentation) has been prepared by Guardian Pharmacy Services, Inc. ("Guardian," t

Guardian Pharmacy Services has issued a presentation outlining its forward-looking statements and business strategy. The company emphasizes its market leadership with more than 40% market share, particularly in the Assisted Living and Memory Care pharmacy markets. However, the presentation also highlights various risks and uncertainties facing the company, including competition, regulatory changes, and supply chain disruptions. The management team possesses substantial experience that could foster effective execution of their strategies despite the outlined challenges.

Read more →
-GRDN
Aug 11, 2025
GRDNGeneral

Guardian Pharmacy Services Reports Second Quarter 2025 Financial Results; Raises Full-Year Guidance

Guardian Pharmacy Services announced its strong financial results for the second quarter of 2025, demonstrating solid growth across multiple metrics. The company raised its full-year revenue and adjusted EBITDA guidance, reflecting better-than-expected performance and effective execution by pharmacy teams. Recent acquisitions in key markets contribute to the anticipated growth, positioning Guardian favorably within the long-term care pharmacy sector. The organization also completed a secondary offering, increasing its public float.

Read more →

About Guardian Pharmacy Services, Inc.

Atlanta, GA 3,600 employees guardianpharmacy.com
Headquarters300 GALLERIA PARKWAY SE, ATLANTA, GA, 30339
BIOPHARMAWATCH ELITE
Trade the next GRDN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime